Gyre Therapeutics (GYRE) Enterprise Value (2010 - 2026)
Gyre Therapeutics (GYRE) reported Enterprise Value of -$14.1 million for Q1 2026, down 179.87% year-over-year from $17.7 million in Q1 2025, and down 251.08% quarter-over-quarter from -$4.0 million in Q4 2025.
Gyre Therapeutics (GYRE) Enterprise Value (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 17 years of Enterprise Value data on file, last reported at -$14.1 million in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$14.1 million, down 179.87% year-over-year; the trailing twelve-month figure through Mar 2026 was -$14.1 million (down 179.87% YoY), and the FY2025 annual result was -$4.0 million, down 148.01% from the prior year.
- Enterprise Value eased to -$14.1 million in Q1 2026 per GYRE's latest filing, from -$4.0 million in the prior quarter.
- Over five years, Enterprise Value peaked at $17.7 million in Q1 2025 and troughed at -$75.4 million in Q2 2022.
- A 5-year average of -$8.9 million and a median of -$4.0 million in 2025 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value soared 564.95% in 2024, then slumped 340.04% in 2025.
- A 5-year view of Enterprise Value shows it stood at $4.5 million in 2022, then tumbled by 182.57% to -$3.7 million in 2023, then soared by 324.62% to $8.4 million in 2024, then slumped by 148.01% to -$4.0 million in 2025, then tumbled by 251.08% to -$14.1 million in 2026.
- Business Quant data shows GYRE's Enterprise Value at -$14.1 million in Q1 2026, -$4.0 million in Q4 2025, and -$24.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -584.73 Mn |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | -14.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.13 Mn |
| Dec 31, 2025 | -4.03 Mn |
| Sep 30, 2025 | -24.55 Mn |
| Jun 30, 2025 | -9.10 Mn |
| Mar 31, 2025 | 17.69 Mn |
| Dec 31, 2024 | 8.38 Mn |
| Sep 30, 2024 | 10.23 Mn |
| Jun 30, 2024 | 7.90 Mn |
| Mar 31, 2024 | 15.85 Mn |
| Dec 31, 2023 | -3.73 Mn |
| Sep 30, 2023 | -2.20 Mn |
| Jun 30, 2023 | -11.53 Mn |
| Mar 31, 2023 | -12.65 Mn |
| Dec 31, 2022 | 4.52 Mn |
| Sep 30, 2022 | -23.10 Mn |
| Jun 30, 2022 | -75.39 Mn |
| Mar 31, 2022 | -34.82 Mn |
| Dec 31, 2021 | -46.85 Mn |
| Sep 30, 2021 | -64.53 Mn |
| Jun 30, 2021 | -86.52 Mn |